These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 14662107)

  • 1. Fibrates for treatment of the metabolic syndrome.
    Maki KC
    Curr Atheroscler Rep; 2004 Jan; 6(1):45-51. PubMed ID: 14662107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
    Idzior-Waluś B
    Przegl Lek; 2001; 58(10):924-7. PubMed ID: 11957820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
    Boden WE
    Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.
    Najib J
    Clin Ther; 2002 Dec; 24(12):2022-50. PubMed ID: 12581543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
    Keating GM; Croom KF
    Drugs; 2007; 67(1):121-53. PubMed ID: 17209672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives.
    Chapman MJ
    Atherosclerosis; 2003 Nov; 171(1):1-13. PubMed ID: 14642400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II).
    Deedwania PC; Maki KC; Dicklin MR; Stone NJ; Ballantyne CM; Davidson MH
    J Cardiometab Syndr; 2006; 1(5):295-300. PubMed ID: 17679790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
    Brown WV
    Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study.
    Kim NH; Han KH; Choi J; Lee J; Kim SG
    BMJ; 2019 Sep; 366():l5125. PubMed ID: 31562117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrates, dyslipoproteinaemia and cardiovascular disease.
    Watts GF; Dimmitt SB
    Curr Opin Lipidol; 1999 Dec; 10(6):561-74. PubMed ID: 10680050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of dyslipoproteinemia in the metabolic syndrome.
    Steinmetz A; Fenselau S; Schrezenmeir J
    Exp Clin Endocrinol Diabetes; 2001; 109(4):S548-59. PubMed ID: 11453042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM; Ormrod D
    Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting dyslipidemia in the metabolic syndrome: an update.
    Paraskevas KI; Karatzas G; Pantopoulou A; Iliopoulos DG; Perrea D
    Curr Vasc Pharmacol; 2010 Jul; 8(4):450-63. PubMed ID: 19485929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrates and microvascular complications in diabetes--insight from the FIELD study.
    Ansquer JC; Foucher C; Aubonnet P; Le Malicot K
    Curr Pharm Des; 2009; 15(5):537-52. PubMed ID: 19199980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of cardiovascular disease utilizing fibrates--a pooled meta-analysis.
    Loomba RS; Arora R
    Am J Ther; 2010; 17(6):e182-8. PubMed ID: 20535009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
    Scott R; O'Brien R; Fulcher G; Pardy C; D'Emden M; Tse D; Taskinen MR; Ehnholm C; Keech A;
    Diabetes Care; 2009 Mar; 32(3):493-8. PubMed ID: 18984774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
    Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.